Archives
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Patients with AAG often respond to intravenous immunoglobuli
2023-09-28

Patients with AAG often respond to intravenous immunoglobulin or plasma exchange. If these therapies are inadequate, ongoing immune suppression with steroids, azathioprine, mycophenylate or rituximab have been shown to be effective in case reports. Our patient seemed initially resistant to steroid t
-
br ARIs in the prevention of
2023-09-27

5ARIs in the prevention of prostate cancer Prostate cancer continues to be a leading cause of male deaths worldwide. In 2009, it was estimated there would be 192,280 new cases of prostate cancer with a predicted 27,360 deaths [25]. Because androgens, and specifically DHT, play a large role in bot
-
Previously several genes such as cytokine Lyu
2023-09-27

Previously, several genes such as cytokine (Lyu and Park, 2007), cell motility-associated genes (Schotterl et al., 2017), transforming growth factor-β (TGF-β), TGF-β receptor II which is a cell surface receptor with serine/threonine kinase activity (Jiang et al., 2014, Schotterl et al., 2017), cell
-
br Materials and methods br Results The clinical characteris
2023-09-27

Materials and methods Results The clinical characteristics of the two selected groups are shown in Table 1. As shown in Table 1, the enzyme activity of ATX in CSF of MS patients (59.90±3.09nmol/min/ml±SEM) was significantly higher (p Discussion Numerous studies have so far shown that ATX tak
-
In this report the natural compound deguelin
2023-09-27

In this report, the natural compound deguelin potently and dose-dependently suppressed Aurora B kinase activity in vitro, indicating that this compound is an effective Aurora B inhibitor. The docking study indicated that deguelin was docked into the ATP-binding pocket of Aurora B and formed hydropho
-
Then Autodock was employed for site directed docking on AD
2023-09-27

Then, Autodock4.2 was employed for site directed docking on AD with the ligands of the cluster(s) having high binding affinities in VS II experiment (Morris et al., 2009). Docking protocols were followed as per our earlier report with 200 GA (genetic algorithm) run (Kalani et al., 2015). Likewise, l
-
Apoptosis a major process of programmed cell death
2023-09-27

Apoptosis, a major process of programmed cell death, and in response to many chemopreventive agents (Jeyamohan et al., 2016). In general, two major signaling pathways control apoptosis, namely, a pathway mediated by cell death receptor and a pathway mediated by mitochondrion, and possible drug targe
-
ARG I is one of the most
2023-09-27

ARG I is one of the most important mammalian enzymes responsible for nitrogen metabolism since it comprises the main route for the elimination of excess nitrogen resulting from amino VX-770 sale and nucleotide metabolism [18]. ARG I deficiency leads to hyperargininemia, characterized by progressive
-
Current treatment options for corneal neovascularization inc
2023-09-27

Current treatment options for corneal neovascularization include topical application of steroids220, 25, 35, 43 or surgical interventions: laser ablation,14, 203, 234, 48 photodynamic therapy (PDT),4, 93 and fine-needle diathermy.221, 238, 240, 261 Targeting proangiogenic molecules with topical or s
-
Although AMPK is a negative regulator of bioenergetic reprog
2023-09-27

Although AMPK is a negative regulator of bioenergetic reprogramming in cancer cells, little is known about the role of AMPK in immunometabolism in sepsis. Our current study indicates that AMPKα dysfunction enhances PKM2-dependent aerobic glycolysis, which results in HMGB1 release in macrophages and
-
br Experimental section br Abbreviations PSA puromycin
2023-09-27

Experimental section Abbreviations PSA, puromycin–sensitive aminopeptidase; APN, aminopeptidase N; AML, acute myeloid Leukemia; ALL, acute lymphoblastic leukemia; AADR, amino Fmoc-Gly-OPfp deprivation response; PAN, puromycin aminonucleoside; DCC, dicyclohexyl carbodiimide; NHS, N–hydroxy succ
-
Here we have used transcriptome
2023-09-27

Here, we have used transcriptome analysis of primary neonatal rat cardiomyocytes treated with either the ETR agonist endothelin-1 or the α1-AR agonist phenylephrine to assess differences in their respective signalling networks, and further probed these differences using a panel of fluorescent resona
-
Although effects of low concentrations
2023-09-26

Although effects of low concentrations of agonist were not as thoroughly documented for heteromeric receptors such as the major Polyphyllin VII α4β2 nAChR, a similar mechanism of action was described to explain the potentiation of these receptors with low concentrations of acetylcholine-esterase-in
-
The most potent compounds within the
2023-09-26

The most potent compounds within the current series of compounds were therefore , , , , and , with Safingol australia possessing the best selectivity towards the lyase reaction in comparison to the hydroxylase reaction, indeed, this compound was found to possess an IC value of 1210nM against the 17α
-
Although we have achieved a
2023-09-26

Although we have achieved a great deal of success in the development of tools to understand autophagy in health and disease, highly specific reagents for autophagy manipulation and deep knowledge of autophagy is required to advance the research in therapeutic treatment. Better disease (ischemia) ani
16350 records 292/1090 page Previous Next First page 上5页 291292293294295 下5页 Last page